The neuropathology of progressive supranuclear palsy (PSP) involves accumulation of neuronal and glial hyperphosphorylated 4‐repeat tau (4RT) pathology with associated neurodegeneration,1 and a clinical diagnosis of PSP is strongly predictive of underlying PSP pathology at postmortem.2 The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.